U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07528911) titled 'Elements of Adaptive Immunity in Epithelial Ovarian Cancer' on July 23, 2025.
Brief Summary: The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Study Start Date: April 01, 2023
Study Type: OBSERVATIONAL
Condition:
Epithelial High Grade Serous Ovarian Cancer
Intervention:
OTHER: Assessment of elements of adaptive immunity in tumor biopsies
Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated ...